Effect of Lyophilization on Stability of PEG-Protein Conjugate: a Case Study with Peginterferon alfa-2b
DOI:
https://doi.org/10.1590/s2175-97902023e201120Keywords:
Depegylation, Lyophilization, Stability, Residual moisture content, Peginterferon alfa-2bAbstract
The purpose of the present study was to develop stable lyophilized formulation of peginterferon alfa-2b which is acquiescent to the short lyophilization process. The present study evaluates the effect of buffering components and cryoprotectant(s) on depegylation of the peginterferon alfa-2b in combination with lyophilization process. Finally, a short lyophilization process was identified which can produce a stable pharmaceutical form of peginterferon alfa-2b without any depegylation during long-term storage. Formulations were analyzed mainly for depegylation by HP-size exclusion chromatography and in-vitro antiviral activity. Residual moisture content in the lyophilized product was also used as a key indicating parameter to check its role with respect to depegylation upon storage under various temperature conditions. It was observed that the peginterferon alfa-2b when formulated in presence of cryoprotectant like sucrose requires longer lyophilization process of about 5 days, irrespective of the buffering components used, to reduce the level of residual moisture content and thereby to produce the stable formulation without depegylation. A stable formulation in presence of high concentration of lactose as a cryoprotectant was developed which can withstand stresses exerted to protein-polymer conjugate during lyophilization phases without any significant depegylation. A short lyophilization process of about 48 hours can be utilized for peginterferon alfa-2b when formulated in presence of lactose as a cryoprotectant through which a stable lyophilized formulation can be produced as against longer process required when sucrose is used a cryoprotectant, which is essential from commercial point of view as lyophilization is a costly process.
Downloads
References
Bjelošević M, Seljak KB, Trstenjak U, Logar M, Brus B, Grabnar PA. Aggressive conditions during primary drying as a contemporary approach to optimise freeze-drying cycles of biopharmaceuticals. Eur J Pharm Sci. 2018;122:292-302.
Foster GR. Pegylated interferons for the treatment of chronic hepatitis C. Drugs. 2010;70(2):147-65.
Ishihara H. Current status and prospects of polyethylene glycol-modified medicines. Biol Pharm Bull. 2013;36(6):883-8.
Kozlowski A, Harris JM. Improvements in protein PEGylation: pegylated interferons for treatment of hepatitis C. J Control Release. 2001;72(1-3):217-24.
Lim JY, Lim DG, Kim KH, Park SK, Jeong SH. Effects of annealing on the physical properties of therapeutic proteins during freeze drying process. Int J Biol Macromol. 2018;107:730-40.
MacLeod SK. Moisture determination using Karl Fischer titrations. Anal Chem. 1991;63(10):557A-66A.
Matthews SJ, McCoy C. Peginterferon alfa-2a: a review of approved and investigational uses. Clin Ther. 2004;26(7):991-1025.
McHutchison JG, Fried MW. Current therapy for hepatitis C: pegylated interferon and ribavirin. Clin Liver Dis. 2003;7(1):149-61.
Mosharraf M, Malmberg M, Fransson J. Formulation, lyophilization and solid-state properties of a pegylated protein. Int J Pharm. 2007;336(2):215-32.
Murtaugh MP, Baarsch MJ, Zhou Y, Scamurra RW, Lin G. Inflammatory cytokines in animal health and disease. Vet Immunol Immunopathol. 1996;54(1-4):45-55.
Ohori R, Akita T, Yamashita C. Effect of temperature ramp rate during the primary drying process on the properties of amorphous-based lyophilized cake, Part 2: Successful lyophilization by adopting a fast ramp rate during primary drying in protein formulations. Eur J Pharm Biopharm. 2018;130:83-95.
Turecek PL, Bossard MJ, Schoetens F, Ivens IA. PEGylation of biopharmaceuticals: a review of chemistry and nonclinical safety information of approved drugs. J Pharm Sci. 2016;105(2):460-75.
Wang YS, Youngster S, Grace M, Bausch J, Bordens R, Wyss DF. Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications. Adv Drug Deliv Rev. 2002;54(4):547-70.
Yang L, Xu L, Li Y, Li J, Bi Y, Liu W. Molecular and functional characterization of canine interferon-epsilon. J Interferon Cytokine Res. 2013;33(12):760-8.
Yu P, Zheng C, Chen J, Zhang G, Liu Y, Suo X, et al. Investigation on PEGylation strategy of recombinant human interleukin-1 receptor antagonist. Bioorg Med Chem. 2007;15(16):5396-405.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on-line journal has open and free access.
